141549-86-2

Usage

Uses

Used in Pharmaceutical Synthesis:
3,9-Diazabicyclo[3.3.1]nonan-7-amine,3,9-dimethyl-,endo-(9CI) is used as an intermediate in the synthesis of Indisetron (I532500), a 5-HT3 receptor antagonist. 3,9-Diazabicyclo[3.3.1]nonan-7-amine,3,9-dimethyl-,endo-(9CI) is particularly effective as an antiemetic agent, helping to alleviate nausea and vomiting associated with various conditions and treatments.
Used in Digestive Tract Disorder Treatment:
In the medical industry, 3,9-Diazabicyclo[3.3.1]nonan-7-amine,3,9-dimethyl-,endo-(9CI) is utilized for the treatment of digestive tract disorders. Its role in the synthesis of Indisetron, a potent antiemetic, makes it a valuable component in addressing issues such as gastroenteritis, postoperative nausea, and chemotherapy-induced emesis.

Upstream product

• 852052-29-0 methyl (2E,2'E)-4-(N-methyl-N-methoxycarbonylallylamino)-but-2-enoate 
• 141549-84-0 7-oxo-3,9-dimethyl-3,9-diazabicyclo-[3.3.1]nonane 
• 141549-87-3 3,9-dimethyl-3,9-diazabicyclo<3.3.1>nonan-7-one oxime 

Relevant academic research and scientific papers

Pyrimidine derivatives

Pyrimidine derivatives useful as a gastrointestinal prokinetic agent, represented by formula STR1 wherein X is O or NR5, Y is O, S or NR5 wherein R5 is a hydrogen atom, a C1 -C6 alkyl group or the like; R1 and R2 may be the same or different and each is a hydrogen atom, a C1 -C6 alkyl group or the like; R3 is CN, or COOR6 wherein R6 is a C1 -C6 alkyl group, a C3 -C6 cycloalkyl group, an aryl group or the like; R4 is --SR7 or --NR8 R9 wherein R7 is a C1 -C6 alkyl group; R8 is a C1 -C6 alkyl group or the like; R9 is a hydrogen atom, a C1 -C6 alkyl group or the like, or R8 and R9 may represent, together with the nitrogen atom to which they are attached, an N-substituted piperazine ring of formula (X) STR2 wherein R10 represents a C1 -C6 alkyl group or the like or a pharmacologically acceptable salt thereof. The above-mentioned compounds are useful as a gastrointestinal prokinetic agent used for the therapy of digestive tract diseases.

Synthesis of (endo) 3,9-Disubstituted Diazabicyclononan-7-amines

The novel synthesis of a series of 3,9-diazabicyclononan-7-amines (4) is reported via an alane reduction of a key intermediate oxime (8).The stereoselectivity of the reduction is highly dependent on the size of the 3-aza substituent.

AZABICYCLO DERIVATIVES AND THEIR USE AS ANTIEMETICS

Azabicyclo derivatives of formula (I) and pharmaceutically acceptable salts thereof: STR1 wherein A is a group of formula (a), (b) or (c): STR2 wherein R 1 is hydrogen, C 1-C 10 alkyl, aralkyl or di(C 1-C 4) alkylamino(C 1-C 6)alkyl; R 2, R 3 and R 4 may be the same or different and each is hydrogen, amino, halogen, C 1-C 4 alkoxy or phthalimide; X is O or NH;R is C 1-C 4 alkyl; and Y is NR, O or S;having 5-HT 3 receptor antagonist activity.